Gene Marking and Autologous Bone Marrow Transplantation

MALCOLM K. BRENNER, DONNA R. RILL, ROBERT C. MOEN, ROBERT A. KRANCE, HELEN E. HESLOP, JOSEPH MIRRO, W. FRENCH ANDERSON, JAMES N. IHLE

Research output: Contribution to journalArticle

40 Scopus citations

Abstract

If residual cancer cells in harvested bone marrow could be marked and subsequently detected in patients at relapse, valuable information would be obtained about the source of recurrent disease after autologous marrow transplantation. If normal progenitor cells were also marked, the study would provide useful data on the susceptibility of these human cells to gene transfer and their capacity to express newly introduced genes. We transferred the neomycin-resistance gene (Neo(R)) into bone marrow cells harvested from 20 children with acute myeloid leukemia (n = 12) or neuroblastoma (n = 8) in clinical and cytological remission using a retrovirus vector. The cells were then returned to the patients as part of an autologous bone marrow transplantation protocol. Two AML and three neuroblastoma patients have relapsed. In all, the resurgent cells contained the Neo(R) marker by analysis with PCR. These results prove that so-called remission marrow can contribute to relapse in patients who receive autologous transplants. The gene marking technique is now being used to evaluate techniques of pretransplant purging.

Original languageEnglish (US)
Pages (from-to)204-215
Number of pages12
JournalAnnals of the New York Academy of Sciences
Volume716
Issue number1
DOIs
StatePublished - May 1994

ASJC Scopus subject areas

  • Neuroscience(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • History and Philosophy of Science

Fingerprint Dive into the research topics of 'Gene Marking and Autologous Bone Marrow Transplantation'. Together they form a unique fingerprint.

Cite this